Project Grant R43AR086014
Award Date
8/1/25
Completion Date
3/31/26
Dollars Obligated
$313K
Awardee
Cadenzamed LLC (KY4YSEPMCDZ1)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Wayne, PA, USA
Similar Awards
This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop computational tools to accurately predict and interpret different patterns of knee pain in patients with osteoarthritis. The $348,680 award, with a period of performance from Sep 26, 2024 to Aug 31, 2026, will enable researchers at the University of Arizona to: 1) Adapt a...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop optical redox imaging (ORI) as a diagnostic and evaluative tool for osteoarthritis (OA) and other cartilage diseases. The $359,207 award, valid from September 1, 2024 to August 31, 2028, will be used to: 1) develop a stress test to diagnose cartilage disease based on changes in ORI...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $456,808 to the Buck Institute for Research on Aging to develop innovative mass spectrometry imaging (MSI) technologies and perform deep proteomic profiling of bone tissues. The goal is to spatially visualize changes in the extracellular matrix and glycans related to osteoarthritis,...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,066,302 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Massachusetts Medical School. The grant, effective April 1, 2025 through March 31, 2029, will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), a rich 16-year observational study with comprehensive...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,657,392 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Pittsburgh. The grant funds research to repurpose FDA-approved drugs for the treatment of osteoarthritis (OA) using high-throughput screening in microphysiological models. The project aims to define the capacity of FDA-approved drugs to reverse cartilage-driven and inflammation-driven OA...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $196,460 to the University of Pittsburgh to test a novel microphysiological system as a tool to study neuroimmune interactions in osteoarthritis pain. The goal is to use this system, which includes cartilage, synovial-like, and innervated tissue, to investigate the influence...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $206,023 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Cornell University to investigate mechanotransduction pathways in injured cartilage. The project aims to determine how local peak strain magnitude and manipulation of calcium-dependent signaling or mitochondrial bioenergetics affect the distribution of chondrocyte phenotypes after impact injury, using a novel...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA Program 93.846 Arthritis, Musculoskeletal and Skin Diseases Research, provides $306,858 to Mira Medical, LLC to develop a machine learning framework called the Forearm Fracture AI-Driven Recommendation System (FFAIRS). The goal is to leverage AI to generate treatment recommendations for pediatric forearm fractures based on clinical presentation and X-ray analysis....
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...